Investment Thesis

.

Competitive Moat

characterized by scale economies and intangible assets, including a vast portfolio of established brands and a well-integrated global distribution network. Its scale allows Viatris to maintain cost advantages while ensuring a wide market reach, which is crucial in the pharmaceutical industry. The durability of this moat is expected to remain robust over the next 5-10 years, though the company faces competition from generic manufacturers and emerging biotech firms that may erode market share in certain therapeutic areas.

Growth Engine

Future revenue growth for Viatris is anticipated to stem from several key areas: the expansion of its biosimilars portfolio, increased market penetration in emerging markets, and strategic collaborations that enhance its product offerings. The total addressable market (TAM) for biosimilars is projected to grow significantly, driven by rising healthcare costs and the need for affordable alternatives to branded biologics. Viatris is effectively gaining market share in the biosimilars space, which is integral for its organic growth strategy, while remaining open to acquisition opportunities to bolster its product pipeline.